Bronchopulmonary Dysplasia - Pipeline Insight, 2024

This “Bronchopulmonary Dysplasia - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Bronchopulmonary Dysplasia: Understanding

Bronchopulmonary Dysplasia: Overview

Bronchopulmonary dysplasia (BPD) is a serious lung condition primarily affecting premature infants, particularly those born before 32 weeks of gestation or with low birth weight. It is characterized by abnormal lung development and inflammation, often a result of prolonged oxygen therapy or mechanical ventilation required to support immature lungs. Infants with BPD experience difficulty breathing and may require long-term respiratory support, increasing their risk for further respiratory complications. The signs and symptoms of bronchopulmonary dysplasia (BPD) typically emerge in premature infants who require oxygen therapy or mechanical ventilation. Common symptoms include rapid or labored breathing (tachypnea), persistent need for supplemental oxygen, wheezing, and difficulty feeding. These infants may also show signs of poor growth and have episodes of cyanosis, where the skin appears bluish due to low oxygen levels. In severe cases, infants with BPD may develop chronic lung disease, experiencing frequent respiratory infections and needing long-term respiratory support.

The diagnosis of bronchopulmonary dysplasia (BPD) is typically made in premature infants who continue to require oxygen therapy or respiratory support after 28 days of life, especially if they are born before 32 weeks of gestation. BPD is confirmed based on clinical criteria, including the infant's oxygen dependence and radiographic evidence of lung abnormalities, such as hyperinflation, atelectasis, or fibrosis visible on chest X-rays. Physicians also assess the severity of BPD by evaluating the need for supplemental oxygen at 36 weeks postmenstrual age.

The treatment of bronchopulmonary dysplasia (BPD) focuses on managing symptoms and supporting lung development in affected infants. Key treatments include prolonged oxygen therapy or mechanical ventilation to maintain adequate oxygen levels, along with diuretics to reduce fluid buildup in the lungs and corticosteroids to minimize inflammation. Nutritional support is also crucial for promoting lung growth and overall development, while medications like bronchodilators can help open airways and improve breathing.

"Bronchopulmonary Dysplasia - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchopulmonary Dysplasia pipeline landscape is provided which includes the disease overview and Bronchopulmonary Dysplasia treatment guidelines. The assessment part of the report embraces, in depth Bronchopulmonary Dysplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bronchopulmonary Dysplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Bronchopulmonary Dysplasia R&D. The therapies under development are focused on novel approaches to treat/improve Bronchopulmonary Dysplasia.

Bronchopulmonary Dysplasia Emerging Drugs Chapters

This segment of the Bronchopulmonary Dysplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bronchopulmonary Dysplasia Emerging Drugs

OHB-607: Oak Hill Bio

OHB-607, previously known as TAK-607, is a novel therapeutic candidate developed by Oak Hill Bio, aimed at addressing significant health challenges faced by extremely premature infants. This investigational drug is a recombinant version of insulin-like growth factor 1 (IGF-1), combined with its binding protein IGFBP-3. It is specifically designed to prevent bronchopulmonary dysplasia (BPD). OHB-607 aims to restore IGF-1 levels to those typically present in full-term pregnancies, thereby supporting the normal growth and development of vital organs like the lungs, brain, and eyes. Currently, the drug is in the Phase II stage of its development for the treatment of Bronchopulmonary dysplasia.

AT-100: Airway Therapeutics, Inc

Zelpultide alfa, also known as AT-100, is a novel biologic developed by Airway Therapeutics, Inc. It is a recombinant version of the human surfactant protein D (rhSP-D), engineered to reduce inflammation and infection while modulating the immune response. This therapeutic candidate primarily targets bronchopulmonary dysplasia (BPD). Currently, the drug is in the Phase I stage of its development for the treatment of Bronchopulmonary dysplasia.

Bronchopulmonary Dysplasia: Therapeutic Assessment

This segment of the report provides insights about the different Bronchopulmonary Dysplasia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bronchopulmonary Dysplasia

There are approx. 10+ key companies which are developing the therapies for Bronchopulmonary Dysplasia. The companies which have their Bronchopulmonary Dysplasia drug candidates in the most advanced stage, i.e. Phase II include, Oak Hill Bio and Medipost Co., Ltd.

Phases

The report covers around 12+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of:
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bronchopulmonary Dysplasia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchopulmonary Dysplasia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchopulmonary Dysplasia drugs.

Bronchopulmonary Dysplasia Report Insights

• Bronchopulmonary Dysplasia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bronchopulmonary Dysplasia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bronchopulmonary Dysplasia drugs?
• How many Bronchopulmonary Dysplasia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchopulmonary Dysplasia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bronchopulmonary Dysplasia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bronchopulmonary Dysplasia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Medipost Co., Ltd.
• Oak Hill Bio
• EXO Biologics S.A.
• Airway Therapeutics, Inc

Key Products

• Pneumostem
• OHB-607
• Endotracheopulmonary instillation
• AT-100

This product will be delivered within 2 business days.